Press Releases
Back to Previous Page
 


News Release
November 14, 2016
Your Contact:
Karen Tiano +1 978-495-0093

MilliporeSigma Launches Next-Generation Technology for Advanced Live Cell Imaging
  • Allows more precise control and manipulation of cell culture environments
  • Converts microscope into powerful, state-of-the-art tool for live cell imaging

Billerica, Massachusetts, November 14, 2016 MilliporeSigma has launched the CellASIC® ONIX2 Microfluidic System for advanced live cell imaging. The system converts laboratory microscopes into powerful tools for live cell imaging to more effectively perform in-depth analysis of cellular mechanisms and behavior in a live environment.

The next-generation CellASIC® ONIX2 system allows precise control and manipulation of cell culture environments and provides constant, stable imaging conditions while preserving the health of cells.

“Live cell imaging is an essential instrument for researchers, allowing them to deepen their understanding of biological function, accelerating life-saving or life-extending therapies,” said Jason Apter, Head of Research Solutions Strategic Marketing & Innovation, Life Science. “With the new CellASIC® ONIX2 system, MilliporeSigma is bringing this powerful tool to researchers in a reliable and easy-to-use system that helps them address their most pressing scientific questions.”

The all-in-one system includes a controller that maintains environmental conditions, with application-specific microfluidic plates and intuitive software. With MilliporeSigma’s CellASIC® ONIX2 Microfluidic System, researchers can monitor cellular responses to environmental changes such as media, stimulants, temperature and gas and track individual cells over time. By using microfluidic technology and a small cell culture chamber, these changes can be done faster and more consistently compared with traditional cell cultures. The system’s cell culture platform can be used by drug discovery, basic and applied microbiological and mammalian cell researchers conducting semi-automated, repeatable long-term experiments while continuously collecting quantitative image-based data.

“Microfluidic technology is changing the way we perform live cell analysis,” said Dr. Jintao Liu, Researcher at the Suel Lab, University of California San Diego. “The CellASIC® ONIX microfluidic system is amazingly easy to use yet highly adaptable, which greatly reduces the barrier to adopting this emerging technology.”

The CellASIC® ONIX2 system provides a new level of reliability to researchers studying long-term growth, movement, signaling and cellular interactions and responses to environmental stimuli, including hypoxia and cancer cell behavior. The system’s high-resolution capabilities are ideal for laboratories interested in producing time-lapse cell culture videos or developing cell-based assays and optimizing parameters for short- or long-term cultures.

About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA of Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.